Joint (JYNT) AI Stock Analysis

• Market Cap: $118.14M
• Dividend Yield: N/A
• Average Volume (3M): 133.85K
• Price to Earnings (P/E): 32.0
• Beta (1Y): 1.07
• Revenue Growth: -54.93%
• EPS Growth: N/A
• Country: US
• Employees: 443
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.06
• Shares Outstanding: 14,114,334
• 10 Day Avg. Volume: 93,155
• 30 Day Avg. Volume: 133,848
• PEG Ratio: -0.34
• Price to Book (P/B): 8.77
• Price to Sales (P/S): 2.40
• P/FCF Ratio: 394.27
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 1.92
• Enterprise Value/Gross Profit: 2.51
• Enterprise Value/Ebitda: 111.16
• 1Y Price Target: $9.64
• Price Target Upside: 13.81% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): 0.27
• Revenue Forecast (FY): $60.40M

• Rating: 53 Neutral
• Price Target: $8.50 ▲(0.35% Upside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is driven primarily by mid-range fundamentals: improved net profitability and conservative leverage are outweighed by volatile revenue, inconsistent operating profitability, and a sharp 2025 drop in operating/free cash flow. Earnings-call guidance and the refranchising plan provide a meaningful positive offset, while bearish technicals and a high P/E with no dividend keep the overall rating constrained.

Positive Factors

Refranchising / Business Model Shift

The deliberate move to a pure-play franchisor through refranchising materially reduces capital intensity and operating overhead. Completing this transition mid-2026 should boost recurring royalty revenue, improve operating leverage, and make future growth more FCF-accretive and scalable over the next 2–6 months and beyond.

Improving Profitability

Reported EBITDA and net income improvements reflect structural progress from franchise conversions and cost actions. Sustained margin recovery supports a more durable earnings base as corporate clinic exposure falls, enabling higher future adjusted EBITDA margins if refranchising targets and cost discipline persist.

Conservative Leverage

Low debt-to-equity reduces refinancing and solvency risk while providing flexibility to fund refranchising, marketing, or opportunistic buybacks. Improved ROE indicates management is beginning to convert asset base to profits, supporting balance-sheet resilience during the franchise transition.

Negative Factors

Weak Cash Generation

Sharp deterioration in operating and free cash flow signals earnings quality and working-capital strains; low FCF conversion constrains the firm's ability to fund refranchising costs, national marketing, and buybacks without relying on external liquidity, increasing execution risk over the next several quarters.

Patient Acquisition Headwind

Persistent weakness in new-patient acquisition undermines same-store trends and royalty growth at franchised clinics. Even with marketing fixes, slow patient inflow can limit sustainable top-line recovery and delay the realization of planned post-refranchising margin and cash-flow targets.

Revenue Volatility & Operating Profitability

Volatile revenue and inconsistent operating profitability (including negative EBIT periods) indicate fragile operating leverage and sensitivity to patient flows. This weakens predictability of franchise royalties and may extend the timeline to achieve target EBITDA and net income margins under the franchisor model.

Joint Business Overview & Revenue Model

Company Description

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates in two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and regional developers. As of March 1, 2022, the company operated approximately 700 locations in the United States. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.

How the Company Makes Money

The Joint primarily makes money through a franchise-based model and, to a lesser extent, through revenue from company-owned or company-operated clinics. Key revenue streams include: (1) ongoing royalty fees paid by franchisees, generally tied to clinic sales; (2) initial franchise fees from the sale of new franchise territories/units; and (3) sales of regional developer rights and associated fees where applicable. In addition, the company earns revenue from providing services and support to franchisees, which can include required or optional purchases and programs offered through the franchisor (e.g., training, operational support, and other system-level programs); if specific line-item details are not publicly disclosed, they are null. For company-owned clinics, revenue is generated directly from patient visits and recurring patient programs/memberships sold at the clinic level, with the company bearing the operating costs and retaining the clinic-level gross profit. The scale of the franchise network, new clinic openings, same-store sales at franchised locations (which drive royalty income), and performance of company-owned clinics are significant factors influencing earnings. Specific major partnerships contributing to earnings: null.

Joint Financial Statement Overview

Summary

Profitability rebounded in 2025 with positive net income and very strong gross margins, and leverage is conservative. Offsetting this, revenue has been volatile versus the 2021–2022 peak, operating profitability remains inconsistent (recent negative EBIT), and 2025 cash generation deteriorated sharply with weak free-cash-flow conversion versus earnings.

Income Statement

Revenue has been volatile: strong growth in 2024–2025 off a lower base, but well below the 2021–2022 peak. Profitability has improved meaningfully, with 2025 returning to positive net income (~5.3% margin) after sizable losses in 2023–2024; however, operating profit remains pressured (negative EBIT in 2024–2025) and EBITDA margins have trended down from prior highs (notably weaker than 2023). Gross margins remain very strong, which is a key strength, but the mixed operating leverage and uneven earnings profile keep the score mid-range.

Balance Sheet

Leverage is currently conservative (2025 debt-to-equity ~0.13), which reduces financial risk versus earlier years when debt-to-equity was much higher (2020–2022). Equity has declined from 2023–2025, indicating balance sheet erosion during the loss period, but returns improved sharply in 2025 (positive return on equity ~19%) after negative returns in 2023–2024. Overall, the balance sheet looks cleaner on leverage today, but the shrinking equity base and asset contraction versus 2023 temper the strength.

Cash Flow

Cash generation weakened materially in 2025: operating cash flow fell to ~$1.8M from ~$9.4M in 2024, and free cash flow dropped to ~$0.3M (down ~79% year-over-year). Cash conversion is also a concern—free cash flow covers only a small portion of net income in 2025 (~18%), suggesting earnings quality/cash collection timing is not as strong as the income statement implies. While prior years (2023–2024) showed much stronger free cash flow, the sharp deterioration in the latest period weighs on the score.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	54.90M	52.16M	46.98M	101.25M	80.01M
Gross Profit	42.03M	40.65M	36.50M	92.08M	72.35M
EBITDA	1.90M	2.90M	8.88M	7.89M	10.07M
Net Income	2.91M	-5.80M	-9.75M	626.71K	7.57M
Balance Sheet
Total Assets	60.97M	83.15M	87.21M	93.49M	87.06M
Cash, Cash Equivalents and Short-Term Investments	23.60M	25.05M	18.15M	9.75M	19.53M
Total Debt	2.01M	795.03K	2.86M	26.06M	23.62M
Total Liabilities	45.89M	62.48M	62.44M	60.90M	56.75M
Stockholders Equity	15.05M	20.65M	24.75M	32.56M	30.28M
Cash Flow
Free Cash Flow	334.72K	8.23M	9.68M	2.31M	6.85M
Operating Cash Flow	1.84M	9.42M	14.68M	8.21M	13.84M
Investing Cash Flow	6.27M	-631.55K	-6.19M	-17.90M	-12.75M
Financing Cash Flow	-9.81M	-2.00M	174.12K	328.61K	-2.00M

Joint Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 8.47
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JYNT, the sentiment is Negative. The current price of 8.47 is below the 20-day moving average (MA) of 8.79, below the 50-day MA of 9.23, and below the 200-day MA of 9.75, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 41.74 is Neutral, neither overbought nor oversold. The STOCH value of 21.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JYNT.

Joint Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	78 Outperform	$2.45B	17.67	9.94%	1.80%	23.74%	-18.99%
USPH	62 Neutral	$1.14B	78.68	3.12%	2.25%	17.50%	154.28%
ASTH	62 Neutral	$1.23B	54.15	2.93%	―	68.17%	-85.42%
TOI	54 Neutral	$355.82M	-54.27	759.71%	―	21.67%	16.74%
JYNT	53 Neutral	$118.14M	32.04	-3.70%	―	-54.93%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Joint Corporate Events

Joint Corp Reports Q4 Growth Amid Transformation Strategy

On March 12, 2026, The Joint Corp. reported that fourth quarter 2025 revenue rose 3.1% year on year to $15.2 million, while system-wide sales fell 3.9% and same-store sales declined 3.8%, amid macro headwinds. Quarterly net income improved sharply to $1.0 million from $18,000 a year earlier, consolidated adjusted EBITDA increased 7.8% to $3.6 million, and the company repurchased 1.1 million shares for $9.0 million in the period.

For full-year 2025, revenue grew to $54.9 million from $52.2 million, consolidated net income swung to a $2.9 million profit from a $5.8 million loss, and adjusted EBITDA rose 13.9% to $13.0 million, even as system-wide sales were nearly flat and comp sales turned slightly negative. Management highlighted its “Joint 2.0” transformation, including refranchising 41 clinics in 2025, signing deals to sell additional clinics, and using share repurchases and a stronger balance sheet to support a transition to a pure-play franchisor and a more capital-efficient model.

The Joint ended 2025 with 960 clinics versus 967 a year earlier, reflecting 29 openings, 41 refranchisings and 36 closures, resulting in 885 franchised and 75 company-owned or managed clinics at year-end. The company also increased national marketing spend, improved patient attrition, and achieved faster breakeven for new clinics, positioning the business to benefit from operating leverage and a more resilient profit structure as its multi-year growth initiatives develop.

The most recent analyst rating on (JYNT) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.

Joint Reaches Governance Agreement With Bandera Partners

On January 5, 2026, Joint entered into a letter agreement with Bandera Partners LLC and Jefferson Gramm that provides for Mr. Gramm to be included in the company’s slate of director nominees at its 2026 annual meeting of stockholders and for the board to recommend that shareholders vote in favor of his election. The agreement, which imposes voting commitments, standstill obligations, and transfer restrictions on Bandera’s holdings of Joint’s common stock, is set to remain in effect until the earlier of thirty days before the director-nomination deadline for the 2027 annual meeting or January 21, 2027, signaling a negotiated governance arrangement with an important shareholder through that period.

The most recent analyst rating on (JYNT) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.